Cyril Lervat
Cyril Lervat is an expert in Oncology at Centre Oscar Lambret (France). As of October 2026, ScienceLeadR ranks Cyril Lervat in the top 1% of experts worldwide for Sarcoma. Cyril Lervat has authored 71 publications, the most recent in 2026, and is an investigator in 13 clinical trials, 4 of them ongoing. SLR score: 315 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Pediatrics - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 71
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Ewing Sarcoma in Infants and Children Under 2 Years of Age: A French Retrospective Study. PMID 42720676 — sarcoma, ewing, retrospective studies, neoplasms, drug therapy, sarcoma, therapeutics, child, infant, chemotherapy | Pediatr Blood Cancer | 2026 | 0 |
| [Sarcomas and devices for adolescents and young adults]. PMID 41575117 — sarcoma, adolescent | Rev Prat | 2025 | 0 |
| Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial. PMID 41249450 — sarcoma, ewing, tomography, neoplasms, positron emission tomography computed tomography, maintenance, sarcoma, diagnosis, therapeutics, wounds and injuries | Br J Cancer | 2025 | 0 |
| Rib Ewing Sarcomas in Children and Young Adults: A Large National Retrospective Series. PMID 40913591 — pleural effusion, neoplasms, radiotherapy, adjuvant, sarcoma, multivariate analysis, child | Pediatr Blood Cancer | 2025 | 0 |
| Insights Into Non-Classic Primary Bone Sarcomas in Children, Adolescents, and Young Adults: A French Descriptive Study. PMID 40746226 — radiotherapy, leiomyosarcoma, hemangiosarcoma, neoplasms, chondrosarcoma, sarcoma, adolescent, chordoma, therapeutics, adamantinoma, child, osteosarcoma | Pediatr Blood Cancer | 2025 | 0 |
Clinical Studies 13
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Ongoing Clinical Trials
4 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| INTER EWING 1 International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma Trial 1 2024-511989-36-00 — radiotherapy, sarcoma, ewing, biomedical research, drug therapy, sarcoma, research, chemotherapy | Phase 3 | Recruiting | 2025 |
| Phase Ib study of the combination of regorafenib with conventional chemotherapy for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma REGO INTER EWING1 2023-503322-39-00 — sarcoma, ewing, lung, pleura, drug therapy, sarcoma, neoplasm metastasis, therapeutics, chemotherapy | Phase 1 | Active not recruiting | 2023 |
| Metronomic Chemotherapy in Wilms Tumor (MetroWilms 1906) NCT05384821 — isotretinoin, temozolomide, neoplasms, kidney, drug therapy, vincristine, wilms tumor, kidney neoplasms, etoposide, irinotecan, tretinoin, chemotherapy | Phase 1/Phase 2 | Recruiting | 2022 |
| Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients NCT04698785 — quality of life, body surface area, disease-free survival, progression-free survival, neoplasms, tablets, maintenance, sarcoma, bone neoplasms, diagnosis, tyrosine, therapeutics, osteosarcoma, bone and bones | Phase 2 | Recruiting | 2021 |
LeadR Networks
Main global connection map